← 返回

过继性细胞转移免疫疗法用于癌症

英文原题:Adoptive Cellular Transfer Immunotherapies for Cancer.

查看英文原题

Adoptive Cellular Transfer Immunotherapies for Cancer.

PubMed 2022/05/13(内容时间) Cancer Treat Res Commun Q2 · IF 3.5(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

癌症患者需要有效的治疗方法,因为其疾病导致的死亡率很高。传统疗法,如化疗和放疗,具有严重的副作用。药物发现正致力于开发可能对患者有益效果的替代策略。细胞疗法是潜在的治疗方法,其新产品的产生正在快速增长。该概念涉及分离免疫细胞、体外激活并回输给患者。目标是增强免疫细胞以对抗癌细胞。可以使用不同的免疫细胞,包括树突状细胞、T细胞、NK细胞、巨噬细胞和B淋巴细胞。一些产品已经获得FDA批准,而更多产品目前正在进行临床试验。研究正致力于改善细胞的功能,这可能需要进行基因修饰或与其他疗法联合。最后,开发新技术至关重要,这些技术可用于监测接受细胞疗法患者的免疫特征,以评估治疗的效果。

展开英文摘要原文

Patients with cancer require efficient treatment approaches as the mortality rate due to their disease is high. Conventional therapies, like chemotherapy and radiation, have severe side effects. Drug discovery is focusing on the development of alternative strategies that could have beneficial effects to the patients. Cellular therapies are potential therapeutics, and the generation of new products is growing fast.

The concept involves the isolation of immune cells, ex vivo activation and reinfusion into the patient. The goal is to boost the immune cells to fight cancer cells. Different immune cells can be used, including dendritic cells, T cells, NK cells, macrophages and B lymphocytes. Some products have already gained FDA approval, while many more are currently in clinical trials. Research is focusing on the improvement of the function of the cells that may require genetic modification or combination with other therapies.

Finally, it is crucial to develop novel technologies that could be used in monitoring of the immune profile of patients that have received a cellular therapy to assess the efficacy of the treatment.

论文信息

作者
Parsonidis P、Papasotiriou I
第一作者单位
Research Genetic Cancer Centre S.A., Industrial Area of Florina, Greece.Greece
通讯作者单位
Research Genetic Cancer Centre International GmbH, Zug, Switzerland. Electronic address: papasotiriou.ioannis@rgcc-international.com.Switzerland
文献类型
综述
期刊
Cancer treatment and research communications2022
原文标识
PubMed 35679756 · DOI 10.1016/j.ctarc.2022.100575